



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

December 31, 2019

Richard Kaiser  
Acting Chief Financial Officer  
BioForce Nanosciences Holdings, Inc.  
2020 General Booth Blvd., Unit 230  
Virginia Beach, VA 23454

**Re: BioForce Nanosciences Holdings, Inc.**  
**Preliminary Information Statement on Schedule 14C**  
**Filed December 13, 2019**  
**File No. 000-51074**

Dear Mr. Kaiser:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Richard W. Jones, Esq.